These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20425393)

  • 1. JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
    Vannucchi AM
    Curr Hematol Malig Rep; 2010 Jan; 5(1):22-8. PubMed ID: 20425393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
    Vannucchi AM
    Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
    Guy A; James C
    Med Sci (Paris); 2019; 35(8-9):651-658. PubMed ID: 31532377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ph
    Košťál M; Schwarz J; Ovesná P; Penka M; Dulíček P;
    J Thromb Thrombolysis; 2021 Jan; 51(1):112-119. PubMed ID: 32578055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 mutation-related disease and thrombosis.
    Vannucchi AM; Guglielmelli P
    Semin Thromb Hemost; 2013 Jul; 39(5):496-506. PubMed ID: 23633193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
    Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
    J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.
    Teofili L; Martini M; Iachininoto MG; Capodimonti S; Nuzzolo ER; Torti L; Cenci T; Larocca LM; Leone G
    Blood; 2011 Mar; 117(9):2700-7. PubMed ID: 21212285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.
    Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H
    J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
    Wadleigh M; Gilliland DG
    Curr Hematol Malig Rep; 2006 Jun; 1(2):75-80. PubMed ID: 20425335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
    Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
    Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
    Haybar H; Khodadi E; Shahjahani M; Saki N
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and thrombosis in myeloproliferative diseases.
    Harrison CN
    Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective.
    Singh N; Sharma A; Sazawal S; Ahuja A; Upadhyay A; Mahapatra M; Saxena R
    Clin Appl Thromb Hemost; 2015 Sep; 21(6):579-83. PubMed ID: 25804613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.